Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advances in structural and molecular neuroimaging in Alzheimer's disease.
Ellis KA, Rowe CC, Szoeke CE, Villemagne VL, Ames D, Chételat G, Martins RN, Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Ellis KA, et al. Among authors: ames d. Med J Aust. 2011 Feb 21;194(4):S20-3. doi: 10.5694/j.1326-5377.2011.tb02938.x. Med J Aust. 2011. PMID: 21401483
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Ritchie CW, et al. Among authors: ames d. Arch Neurol. 2003 Dec;60(12):1685-91. doi: 10.1001/archneur.60.12.1685. Arch Neurol. 2003. PMID: 14676042 Clinical Trial.
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Lannfelt L, et al. Among authors: ames d. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Lancet Neurol. 2008. PMID: 18672400 Clinical Trial.
Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.
Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S. Fripp J, et al. Among authors: ames d. Neuroimage. 2008 Nov 15;43(3):430-9. doi: 10.1016/j.neuroimage.2008.07.053. Epub 2008 Aug 12. Neuroimage. 2008. PMID: 18789389
Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study.
Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA; AIBL research group. Sittironnarit G, et al. Among authors: ames d. Dement Geriatr Cogn Disord. 2011;31(3):173-8. doi: 10.1159/000325171. Epub 2011 Mar 9. Dement Geriatr Cogn Disord. 2011. PMID: 21389718
Association of plasma Aß peptides with blood pressure in the elderly.
Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J, Richard F, Cottel D, Berr C, Ames D, Masters CL, Rowe CC, Szoeke C, Tzourio C, Dartigues JF, Buée L, Martins R, Amouyel P. Lambert JC, et al. Among authors: ames d. PLoS One. 2011 Apr 15;6(4):e18536. doi: 10.1371/journal.pone.0018536. PLoS One. 2011. PMID: 21525986 Free PMC article.
645 results